Compare ACADIA Pharmaceuticals Inc. (ACAD) vs NRG Energy Inc (NRG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs NRG Energy Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while NRG Energy Inc trades at $136.32 (market cap $29.12B). The key difference: NRG Energy Inc is far larger — about 6.5× ACADIA Pharmaceuticals Inc.'s market cap, and NRG Energy Inc pays a 1.38% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | NRG | |
|---|---|---|
Market Cap | $4.49B | $29.12B |
Sector | Health | Utilities |
52-Week High | $28.06 | $184.03 |
52-Week Low | $20.06 | $120.65 |
Enterprise Value | $3.69B | $52.95B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
NRG Energy trades at $138.01, up 0.96% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong 2025 results with $30.71B revenue and $864M net income, though Q1 2026 earnings missed expectations. Valuation metrics show a high P/E ratio of 154.96 but attractive P/S of 0.87. Recent corporate actions include a $0.48 dividend payment in May 2026.
Outlook remains cautiously optimistic with 64% analyst buy ratings, though elevated debt levels and recent earnings miss pose risks. The stock offers value through reasonable sales multiples and dividend income, but investors should monitor execution on 2026 EBITDA guidance of $5.3-5.8B and manage exposure to energy market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
